Eliquis, a highly-touted replacement for Warfarin has run into trouble. It was approved by the U.S. Food and Drug Administration (FDA) in December 2012. Now, it’s the target of a number of recently filed lawsuits like those filed by victims of Pradaxa and Xarelto, similar blood thinners that doctors began prescribing in 2010 and 2011.
The Milwaukee Sentinel Journal, a Pulitzer Prize winning news agency, reports that “…at least 8,000 deaths” have been linked to Eliquis, Pradaxa and Xarelto since 2010 “…compared to 700 for Warfarin.” By comparison, it also noted that in 2014 “…Warfarin accounted for roughly three times as many prescriptions.”
Warfarin has an antidote. But there is no antidote for Eliquis, Pradaxa and Xarelto. While Warfarin can cause hemorrhages, Vitamin K can stop the bleeding. Doctors have been prescribing Warfarin for more than 50 years to dissolve life-threatening blood clots that some patients with atrial fibrillation develop in the atria – two chambers in the heart – and clots caused by other conditions that can develop deep in the legs, threatening the heart and the lungs.
TV commercials promoting Eliquis never mention its lack of an antidote. They say it reduces deaths and frees patients from the restrictive diet and frequent blood tests required of those on Warfarin.
But an expert in the design of clinical drug trials called praise for Eliquis “premature.” Based on his review of FDA documents submitted to the federal agency before Eliquis was approved, F. Perry Wilson, a Yale University medical school professor, questioned the accuracy of trials showing that Eliquis reduces deaths.
Those who lost loved ones to Eliquis are filing law suits against the drug’s manufacturers. The suits charge that the victims were never warned that Eliquis had no antidote, that medical trials conducted before its approval were flawed and that records were falsified.
The Wayne Wright law firm has years of experience fighting drug companies that misrepresent the benefits of their products and hide deadly side effects as they compete for profits in the multi-billion dollar prescription drug market.
The firm has been successfully fighting back against drug companies on behalf of patients who were not informed about a drug’s disastrous potential before they lost their lives or were permanently crippled by its side effects.